Furthermore, ACE inhibitors have been reported to reduce the risk of type-2 diabetes in nondiabetic patients at baseline; bradykinin enhances the responsiveness of both muscle fiber and adipocytes to insulin [6]. The gene discussed is ACE; the disease is type 2 diabetes mellitus.